Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis - Extension Study - [EXTENSION OF 700196582]

Trial Profile

Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis - Extension Study - [EXTENSION OF 700196582]

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Alogliptin (Primary)
  • Indications Cardiovascular disorders; Cerebrovascular disorders; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms SPEAD-A Extension
  • Most Recent Events

    • 23 Apr 2018 Status changed from recruiting to active, no longer recruiting.
    • 30 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top